- Trial phase
- Approved
- Time to market
- Already marketed, US FDA approval July 17, 2018; no launch or approval risk remaining.
- Why 3/10
- No hard, dated binary catalyst in the next ~12 months: SYMTUZA was approved in July 2018 and is a mature marketed product whose only recent FDA event was a routine safety-labeling update (April 2026), an approved drug with no pending PDUFA/pivotal readout scores 3-5 per the rubric, and at the low end because it is one small product inside a mega-cap whose stock thesis is driven by oncology/immunology.
For JNJ shareholders, Symtuza is not a stock-moving catalyst, it is a mature, marketed HIV drug with no dated binary in the next year, so there is nothing to trade on the drug itself. Investors seeking HIV single-tablet-regimen exposure with actual catalysts should look to the pure-play HIV names (Gilead, ViiV) rather than JNJ; for JNJ, treat Symtuza as steady-state revenue and monitor quarterly earnings for HIV-franchise trends.
Price Chart
Executive Summary
SYMTUZA is Johnson & Johnson's (Janssen) four-drug, once-daily single-tablet HIV regimen, approved by the FDA on July 17, 2018 as the "first and only complete darunavir-based single-tablet regimen" for HIV-1, later expanded to include pediatric patients. It is a fully marketed, mature product inside a mega-cap pharma whose value is dominated by oncology and immunology franchises, the drug is a stable but immaterial contributor to JNJ's share price, and the stock's modest +2.49% one-day move around its 2018 approval reflects that. There is no scheduled regulatory catalyst for SYMTUZA in the next 12 months; the notable recent event was an April 2026 FDA safety-labeling update on hepatitis B co-infection.
How It Works
One daily pill combining four anti-HIV medicines that attack the virus at different steps: darunavir stops HIV from assembling new copies of itself, cobicistat boosts darunavir's levels so it works harder, and emtricitabine plus tenofovir alafenamide block the virus's copying machinery. Bundling all four into a single tablet is designed to keep the virus suppressed while making it easier to take than several separate pills.
Trial Status
FDA-approved in the US on July 17, 2018 as a complete regimen for HIV-1 in treatment-naive and certain virologically suppressed adults; the Nov 2023 FDA label version covers pediatric patients weighing at least 40 kg; a safety-labeling update recorded April 2026 strengthened the hepatitis B (HBV) co-infection warning about severe acute HBV exacerbations after discontinuation.
The Two-Sided Case
Upcoming Catalysts
- None scheduled for SYMTUZA specifically in the next 12 months (no PDUFA date, no pivotal readout, no dated label-expansion decision).
- Watch for further FDA safety communications or label changes following the April 2026 hepatitis B warning update.
- JNJ quarterly earnings (next ~mid-October 2026) will show HIV-franchise sales trends, but these are not drug-specific binaries.
- Longer-term: competitive dynamics and generic erosion in the HIV single-tablet market.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
JOHNSON & JOHNSON 8-K JNJ ·Originating report